o-acetoxyphenylacetic acid | 17112-85-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: o-acetoxyphenylacetic acid
• 英文别名: o-Acetoxy-phenylessigsaeure；2-(acetyloxy)-benzeneacetic acid；a-Acetoxyphenylacetic acid；2-(2-acetyloxyphenyl)acetic acid
• CAS: 17112-85-5
• 化学式: C₁₀H₁₀O₄
• 分子量: 194.187
• InChiKey: ZRPVTKRYDFLMBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  o-acetoxyphenylacetic acid 在 磷酸 作用下， 以 水 为溶剂， 以93 %的产率得到邻羟基苯乙酸
  参考文献：
  名称：

  一种邻羟基苯乙酸的合成方法

  摘要：

  本发明属于医药中间体合成技术领域，具体涉及一种邻羟基苯乙酸的合成方法。包括以下步骤：(1)以邻烯丙基苯酚为原料，与乙酸酐反应获得邻烯丙基乙酸苯酯；(2)邻烯丙基乙酸苯酯经臭氧氧化、双氧水氧化两步反应获得邻乙酰氧基苯乙酸；(3)邻乙酰氧基苯乙酸水解获得邻羟基苯乙酸。本发明的合成方法条件温和，收率高，无环境污染，适合工业化生产。

  公开号：

  CN116715572A
• 作为产物：
  描述：

  o-Acetoxy-phenylessigsaeure-benzylester 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 生成 o-acetoxyphenylacetic acid
  参考文献：
  名称：

  O-乙酰氧基苯基乙酸，阿司匹林的同系物。

  摘要：

  DOI：

  10.1021/jm00309a048

文献信息

• Methods for treating an inflammatory condition or inhibiting JNK
  申请人：——

  公开号：US20040127536A1

  公开（公告）日：2004-07-01

  This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  这项发明通常涉及吲唑衍生物，具有以下结构： 1 或药用可接受的盐，其中R 1 ，R 2 和A如本文所述定义。这类化合物在治疗对JNK抑制剂有响应的广泛疾病和障碍，如炎症性疾病或障碍中具有用途。因此，还披露了治疗这些疾病和障碍的方法，以及包含一个或多个上述化合物的药物组合物。
• Indazole compounds, compositions thereof and methods of treatment therewith
  申请人：Bhagwat S. Shripad

  公开号：US20050009876A1

  公开（公告）日：2005-01-13

  This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

  这项发明通常涉及使用吲唑化合物来治疗或预防与蛋白激酶相关的疾病，包括酪氨酸激酶，诸如增殖性疾病、炎症性疾病、异常血管生成及其相关疾病、动脉硬化、黄斑变性、糖尿病、肥胖、疼痛等。这些方法包括向有需要的患者施用有效量的吲唑化合物，以抑制、调节或控制酪氨酸激酶信号转导。本文中提供了一种新型的吲唑化合物或其药用可接受的盐。
• Indazole derivatives as JNK inhibitors and compositions and methods related thereto
  申请人：——

  公开号：US20020103229A1

  公开（公告）日：2002-08-01

  Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: 1 wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  本发明公开了作为JNK选择性抑制剂的化合物。本发明的化合物是吲唑衍生物，具有以下结构： 1 其中R 1 ，R 2 和A如本文所述定义。此类化合物在治疗对JNK抑制产生响应的广泛病症方面具有用途。因此，还公开了治疗此类病症的方法，以及包含一个或多个上述化合物的药物组合物。
• PROCESS FOR THE PREPARATION OF 2-HYDROXY-4-PHENYL-3,4-DIHYDRO-2H-CHROMEN-6-YL-METHANOL AND (R)-FESO-DEACYL
  申请人：Ciambecchini Umberto

  公开号：US20130079532A1

  公开（公告）日：2013-03-28

  The present invention regards an improved and industrially advantageous process for the preparation of the 2-hydroxy-4-phenyl-3,4-dihydro-2H-chromen-6-yl-methanol intermediates, also called “feso chromenyl” and (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenol, also called “(R)-feso deacyl”, which are in turn used in the synthesis of fesoterodine and in particular of fesoterodine fumarate. This process utilises reagents which are non-toxic and manageable at industrial level and enables obtaining a new stable and non-hygroscopic crystalline form of the key intermediate “(R)-feso deacyl”, called form B.

  本发明涉及一种改进的且在工业上有利的2-羟基-4-苯基-3,4-二氢-2H-色原-6-基甲醇中间体的制备过程，也称为“feso色原”和(R)-2-[3-(二异丙氨基)-1-苯基丙基]-4-(羟甲基)苯酚，也称为“(R)-feso脱酰”，后者用于合成长效毒蕈碱类药物非索特罗定及其特别是非索特罗定富马酸盐。该过程使用在工业水平上无毒且易于处理的试剂，并且能够获得一种新的稳定且非吸湿性的关键中间体“(R)-feso脱酰”的晶型B。
• [EN] SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS<br/>[FR] SYNTHÈSE DE GAMMA-CARBOLINES FUSIONNÉES À HÉTÉROCYCLES SUBSTITUÉS
  申请人：INTRA CELLULAR THERAPIES INC

  公开号：WO2020131895A1

  公开（公告）日：2020-06-25

  The present invention provides improved methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines.

  本发明提供了改进的方法，用于制备取代杂环融合γ-咔啉，这些中间体在生产中很有用，并提供了制备这些中间体和这些杂环融合γ-咔啉的方法。